References
- DBT. Guidelines on similar biologics: regulatory requirements for marketing authorization in India. 2016. [cited 2019 May 26]:[p. 1–54] https://www.birac.nic.in/webcontent/Guidelines_on_Similar_Biologics_06_10_2017.pdf.
- Seo N, Polozova A, Zhang M, et al. Analytical and functional similarity of amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018;10(4):678–691.
- CDER/CBER, FDA. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guid Ind. 2015. [cited 2021 Jan 26]. https://www.fda.gov/media/135612/download.
- European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2014;44:1–16. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- Kaplon H, Reichert JM. mAbs antibodies to watch in 2019. MAbs. 2019;11(2):219–238.
- Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv. 2012;30(5):1158–1170.
- FDA. Biosimilar product information. [cited 2021 Jun 13]. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
- Harston A. How the U.S. compares to Europe on biosimilar approvals and products in the pipeline. 2019. [cited 2020 Apr 10]. https://www.biosimilarsip.com/2019/05/07/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-4/.
- Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 2012;93(3):917–930.
- Jayapal K, Wlaschin K, Hu W, et al. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem. Eng. Prog. 2007;103:40–47.
- Elvin JG, Couston RG, Van Der Walle CF. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm. 2013;440(1):83–98.
- Fischer S, Handrick R, Otte K. The art of CHO cell engineering: a comprehensive retrospect and future perspectives. Biotechnol Adv. 2015;33(8):1878–1896.
- De Jesus M, Wurm FM. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. Eur J Pharm Biopharm. 2011;78(2):184–188.
- Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA A Cancer J Clin. 2020;70(3):145–164.
- Krasinskas AM. EGFR signaling in colorectal carcinoma. Patholog. Res. Int. 2011;2011:1–6.
- Tol J, Punt CJA. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(3):437–453.
- Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38(1):17–23.
- Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048.
- Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12(5):577–583.
- Peeters M, Balfour J, Arnold D. Review article: panitumumab–a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther. 2008;28(3):269–281.
- Trotta F, Leufkens HGM, Schellens JHM, et al. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol. 2011;29(16):2266–2272.
- Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–685.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55–63.
- Kang J, Kim SY, Vallejo D, et al. Multifaceted assessment of rituximab biosimilarity: the impact of glycan microheterogeneity on Fc function. Eur J Pharm Biopharm. 2020;146:111–124.
- Ito T, Tsumoto K. Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress. Protein Sci. 2013;22:1542–1551.
- Wen J, Batabyal D, Knutson N, et al. A comparison between emerging and current biophysical methods for the assessment of higher-order structure of biopharmaceuticals. J Pharm Sci. 2020;109(1):247–253.
- Garidel P, Hegyi M, Bassarab S, et al. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J. 2008;3(9-10):1201–1211.
- Dolma K, Nagar J, Sahoo DK, Ashish Tracking urea induced unfolding-refolding of six-domain protein gelsolin by SAXS data analysis. Pharma Innov. J. 2018;7:5–11.
- Sagar A, Haleem N, Bashir YM, Ashish. Search for non-lactam inhibitors of mtb β-lactamase led to its open shape in apo state: new concept for antibiotic design. Sci Rep. 2017;7:6204.
- Ashish IJ, Juncadella R, Garg CD, Boone, et al. Conformational rearrangement within the soluble domains of the CD4 receptor is ligand-specific. J. Biol. Chem. 2008;283:2761–2772.
- Yang Y, Guo Q, Xia M, et al. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs. 2015;7(2):440–450.
- Nicolantonio FD, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–5712.
- Tsai MH, Pan CH, Peng CL, et al. Panitumumab-conjugated Pt-drug nanomedicine for enhanced efficacy of combination targeted chemotherapy against colorectal cancer. Adv Healthcare Mater. 2017;6(13):1700111.
- Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58(3):984–990.
- Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59:1236–1243.
- Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 2007;13(16):4664–4666.
- Lee KH, Lee J, Bae JS, et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. MAbs. 2018;10(3):380–396.
- Wienken CJ, Baaske P, Rothbauer U, et al. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 2010;1:1–7.